Astellas Pharma Global Development, Inc.

This study tests a liquid form of mirabegron, a medicine already used in older children and adults, in children aged 6 months to 3 years who have bladder problems due to nerve damage (neurogenic detrusor overactivity). The goal is to see if the medicine helps the bladder hold mor…

This study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer without their cancer growing. About 500 adults…

This study tests a new drug called ASP1570 in adults with advanced solid tumors that have spread or can't be removed. The drug is given alone or with other cancer treatments like pembrolizumab, chemotherapy, or both. The main goals are to check safety, see how well people tolerat…

This study tests a drug called zolbetuximab for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). The drug attaches to this protein and helps the immune system attack the tumor. Participants receive zolbetuximab alone or comb…

This study tests an experimental drug, enfortumab vedotin, in people with advanced solid tumors that have spread. The main goal is to see if the drug can shrink tumors. About 329 adults with various solid tumors will take part. The drug is given by IV and aims to control the dise…

This study tests a new drug called zolbetuximab, which targets a protein (CLDN18.2) found in most pancreatic cancers. It is given along with standard chemotherapy to people whose pancreatic cancer has spread. The goal is to see if adding zolbetuximab helps people live longer and …

This study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a specific gene change (FLT3 mutation). Participants are older or have other health issues that pr…

This study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy can slow down or delay cancer growth in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose …

This early-stage study tests a new drug called zolbetuximab combined with standard chemotherapy for people with advanced pancreatic cancer that has spread. The drug targets a protein on cancer cells to help the immune system attack them. The main goal is to see if the combination…

This early-stage study tests a new drug, ASP2390, in 28 adults with house dust mite allergies. The main goal is to check safety and side effects, and also to see how the immune system responds. Participants receive multiple small doses under the skin to find the best and safest d…

This study tests fezolinetant, a non-hormonal drug, for treating hot flashes in women with hormone-positive breast cancer who are on hormone therapy. About 984 women will take either fezolinetant or a placebo daily for a year. The goal is to see if the drug reduces how often and …

This study follows about 1,000 women going through menopause who have bothersome hot flashes and night sweats. They will start a non-hormonal medicine prescribed by their doctor and report how their symptoms, sleep, and daily life change over 12 weeks. Most visits are done from h…